Viridis Pharmaceutical

Viridis Pharmaceutical is a specialty pharmaceutical company primarily known for its role in the development and commercialization of bremelanotide, marketed under the brand name Vyleesi. The company focuses on addressing unmet medical needs in women's health, specifically targeting Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. Viridis operates through a strategic licensing model, having acquired the exclusive North American rights to bremelanotide from Palatin Technologies in 2009. Following successful clinical development and FDA approval in 2019, the company has engaged in sub-licensing agreements with partners like AMAG Pharmaceuticals and Cosette Pharmaceuticals for commercial distribution. Viridis maintains a lean, virtual corporate structure, focusing on high-value asset management and regulatory strategy.